Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst …

1 day ago · During the last three months, 4 analysts shared their evaluations of Adaptimmune …

CouponFollow Extension

50%
OFF

Mizuho Lowers Adaptimmune Price Target By 50%, Citing Pipeline …

1 day from now

1 day ago · The analyst cited several key developments from the quarter, including both …

investing.com

$3
OFF

Genentech, Adaptimmune Launch Up To $3B Cancer T Cell …

1 day from now

Sep 7, 2021 · Investors responded to the Genentech collaboration with a buying surge that …

genengnews.com

FAQs about Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst … Coupon?

Is adaptimmune Therapeutics a good stock to buy?

Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.40, which is an 89.9% upside from current levels. In a report issued on March 6, Wells Fargo also assigned a Hold rating to the stock with a $2.00 price target. ...

What is adaptimmune Therapeutics (ADAP)?

Begin your TipRanks Premium journey today. Adaptimmune Therapeutics (ADAP) Company Description: Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. ...

Is investing in Adaptimmune Therapeutics risky?

Adaptimmune Therapeutics (NASDAQ: ADAP) is advancing T-cell receptor (TCR) therapies for the treatment of solid tumors. Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk. ...

What are the costs associated with Adaptimmune?

Adaptimmune's operating expenses are high relative to its market capitalization. In Q2, R&D and G&A expenses were $40.448 million and $19.083 million, respectively. To cover these costs, Adaptimmune announced in May that it had signed a loan with Hercules Capital for up to $125 million. ...

Will adaptimmune bring the first TCR-T therapy to the market?

In this article, we take a look at Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market with a U.S. Food and Drug Administration (FDA) approval that marked several firsts. By the time Adaptimmune went public in 2015, its first TCR-T therapy was already being tested in clinical trials. ...

Is Adaptimmune's therapy a new cancer treatment?

The U.S. Food and Drug Administration has approved Adaptimmune's first-of-its-kind treatment for a rare type of cancer in the soft tissues that most often affects young people. ...